---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-011724"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2025-04-11T23:59:59+00:00"
generated_at: "2026-05-23T16:44:39.557405+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioCardia initiates patient enrollment at Emory University for Phase III heart failure trial

## Summary
- Emory University School of Medicine is now enrolling patients with ischemic heart failure in BioCardia's pivotal Phase III CardiAMP HF II trial.
- Dr. Arshed Quyyumi, Professor of Medicine at Emory, will serve as principal investigator for the autologous cell therapy study.
- Trial compares CardiAMP therapy to placebo; target enrollment completion in 2027 based on prior positive results presented at ACC 2025.

## SEC filing metadata
- accession: 0001437749-25-011724
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2025-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774925011724/0001437749-25-011724-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774925011724/bcda20250411_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-011724
- JSON: https://secwatch.observer/filing/0001437749-25-011724.json
- Plain text: https://secwatch.observer/filing/0001437749-25-011724.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.